DUBLIN--(BUSINESS WIRE)--Aug 30, 2018--The "Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report analyzes the competitive field of CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors as of June 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage and differentiates between specific and bi- or multispecific molecules.

The mainly selective, but also bispecific new molecular entities inhibit the negative immune checkpoints, including

CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152) LAG-3 (Lymphocyte Activation Gene 3; CD223) TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2) TIGIT (T-cell Immunoreceptor with Ig and ITIM domains) B7-H3 (CD276) Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4

Immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunological activity against tumors. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), PD-1, and PD-L1 are the most widely studied and recognized inhibitory checkpoint pathways. Drugs blocking these pathways are currently utilized for a wide variety of malignancies and have demonstrated durable clinical activities in a subset of cancer patients.

This approach is rapidly extending beyond CTLA-4 and PD-1/PD-L1. New inhibitory pathways are under investigation, and drugs blocking LAG-3, TIM-3, TIGIT, VISTA, or B7/H3 are being investigated.

At least 35 new molecular entities (NMEs), mostly selective or increasingly bispecific antibodies, inhibiting negative immune checkpoints are in clinical development as monotherapy or in combination with other checkpoint modulators. At least further 19 NMEs are undergoing IND-enabling studies and numerous preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in research and development of mostly recombinant antibodies, targeting negative immune checkpoints, such as CTLA-4, LAG-3, TIM-3, TIGIT, B7-H3, CTLA-4, LAG-3, TIM-3, TIGIT, B7-H3, VISTA, B7-H4, PVRIG, GARP, BTLA. In addition, the report lists company-specific R&D pipelines of inhibitors of negative immune checkpoints.

Competitor projects are listed in a tabular format providing information on:

Drug Codes Target / Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information.

For more information about this report visit https://www.researchandmarkets.com/research/hhg38l/competitor?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005837/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/30/2018 04:35 PM/DISC: 08/30/2018 04:35 PM

http://www.businesswire.com/news/home/20180830005837/en